India could be staring at a national health crisis in the backdrop of its continuing massive reliance on Chinese active pharmaceutical ingredients (APIs), including those used in drugs for high-burden diseases such as diabetes and cardiovascular ailments, according to a report by the professional services firm KPMG and the Confederation of Indian Industry (CII).
China API Juggernaut Rolls On But Can India Recoup?
Report: India’s huge dependence on Chinese active pharmaceutical ingredients (APIs), including in high disease burden areas, poses heightened risks to its health security and requires “urgent interventions.”
More from Manufacturing
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
• By
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs